Neutralising antibodies to interferon beta during the treatment of multiple sclerosis

Journal of Neurology Neurosurgery and Psychiatry

Volumn 73, Issue 5, 2002, Pages 465-469

  Giovannoni, G ^a   Munschauer III, F E ^b   Deisenhammer, F ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

ANTIBODY PRODUCTION; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW;

ANTIBODIES; ANTIBODY-PRODUCING CELLS; ANTIVIRAL AGENTS; CLINICAL TRIALS; HUMANS; IMMUNOASSAY; INTERFERON-BETA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUTRALIZATION TESTS; TREATMENT FAILURE;

EID: 0036828793     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.73.5.465     Document Type: Review

References (54)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000;343:938-52.
2. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995;45:1277-85.
3. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94.
4. PRISM. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-504.
5. European Study Group. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998;352:1491-7.
6. Vial T, Descotes J. Immune-mediated side-effects of cytokines in humans. Toxicology 1995;105;31-57.
7. Antonelli G, Bagnato F, Pozzilli C, et al. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta 1a. J Interferon Cytokine Res 1998;18:345-50.
8. Leroy V, Baud M, De Traversay C, et al. Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C. J Hepatol 1998;28:375-81.
9. Myhr KM, Ross C, Nyland HI, et al. Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive. Neurology 2000;55:1569-72.
10. Hochuli E. Interferon immunogenicity: Technical evaluation of interferon-alpha 2a. J Interferon Cytokine Res 1997;17 (suppl 1): S15-21.
11. Prout, TE. The antigenicity of insulin: A review. J Chron Dis 1962;15:879-85.
12. Moore WV, Leppert P. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Enclocrinol Metab 1980;51:691-7.
13. Lusher JM. Hemophilia treatment. Factor VIII inhibitors with recombinant products: Prospective clinical trials. Haematologica 2000;85:2-5.
14. Deisenhammer F, Reindl M, Harvey J, et al. Bioavailability of interferon beta 1 b in MS patients with and without neutralizing antibodies. Neurology 1999;52:1239-43.
15. WHO. WHO Expert Committee on Biological Standardisation. Thirty-fifth Report. WHO Technical Report Series 725. Geneva: World Health Organisation, 1985.
16. Pungor E Jr, Files JG, Gabe JD, et al. A novel bioassay for the determination of neutralizing antibodies to IFN-beta 1b. J Interferon Cytokine Res 1998;18:1025-30.
17. Pozner B, Petkau J, Oger J. Neutralizing antibodies to interferon-β in the treatment of multiple sclerosis. CNS Drugs 1999;3:225-43.
18. Ross C, Clemmesen KM, Svenson M, et al. Immunogenicity of interferon-beta in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000;48:706-12.
19. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998;50:1266-72.
20. Perini P, Facchinetti A, Bulian P, et al. Interferon-beta (INF-beta) antibodies in interferon-be. Eur Cytokine Netw 2001;12:56-61.
21. Kivisakk P, Alm GV, Fredrikson S, et al. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis. Eur J Neurol 2000;7:27-34.
22. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N EngI J Med 2000;343:898-904.
23. Runkel L, Meier W, Pepinsky RB, et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharmacol Res 1998;15:641-9.
24. Braun DP, Preisler HD. Cytolytic activity of peripheral blood blast cells from patients with acute myeloid leukemia. Leuk Lymphoma 1997;27:459-67.
25. PRISMS-4. Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-36.
26. OWIMS. Evidence of interferon beta-1a dose response in relapsing-remitting MS: The OWIMS Study. The Once Weekly Interferon for MS Study Group. Neurology 1999;53:679-86.
27. IFNB MS Study Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 1996;47:889-94.
28. Rice G. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta. Arch Neurol 2001;58:1297-8.
29. Khan OA, Dhib-Jalbut SS. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive. Neurology 1998;51:1698-702.
30. Antonelli G, Simeoni E, Bagnato F, et al. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J Neurol Sci 1999;168:131-6.
31. Merup M, Engman K, Paul C. Interferon antibodies in thrombocythemia. J Interferon Res 1994;14:187-9.
32. Russo D, Candoni A, Grattoni R. Clinical experience of antibodies to interferon-alpha during treatment of chronic myeloid leukemia. J Interferon Cytokine Res 1997;17 (suppl 1):S47-9.
33. Myhr KM, Riise T, Green Lilleas FE, et al. Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis. Neurology 1999;52:1049-56.
34. Kastrukoff LF, Morgan NG, Zecchini D, et al. Natural killer cells in relapsing-remitting MS: Effect of treatment with interferon beta-1B. Neurology 1999;52:351-9.
35. Perini P, Tiberio M, Sivieri S, et al. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta 1a. Eur Cytokine Netw 2000;11:81-6.
36. Petkau J, White R. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 1997;3:402.
37. Arnason BG, Toscas A, Dayal A, et al. Role of interferons in demyelinating diseases. J Neural Transm Suppl 1997;49:117-23.
38. Price C. Interferon beta in multiple sclerosis. Current policy is sensible. BMJ 1997;314:600-1.
39. Rice GP, Paszner B, Oger J, et al. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 1999;52:1277-9.
40. Rice G. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta. Arch Neurol 2001;58:1297-8.
41. Lusher JM. Inhibitor antibodies to factor VIII and factor IX: Management. Semin Thromb Hemost 2000;26:179-88.
42. Pozzili C, Antonini G, Bagnato F, et al. Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: A randomized trial in multiple sclerosis. J Neural 2002;249:50-6.
43. Herndon RM, Jacobs LD, Coats ME, et al. Results of an ongoing, open-label, safety-extension study of interferon beta-1a (Avonex) treatment in multiple sclerosis. International Journal of Multiple Sclerosis Care 1999;2:1-6.
44. White GC, Greenwood R, Escobar M, et al. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective. Haematologica 2000;85:113-16.
45. Rice GP, Paszner B, Oger J, et al. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 1999;52:1277-9.
46. Sturzebecher, S, Maibauer, R, Heuner A, et al. Pharmacodynamic comparison of single doses of IFN-beta 1a and IFN-beta 1b in healthy volunteers. J Interferon Cytokine Res 1999;19:1257-64.
47. Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1997;49:358-63.
48. Munafo A, Trinchard-Lugan II, Uraglio M, et al. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur J Neurol 2001;5:187-93.
49. Fernandez O, Mayorga C, Luque G, et al. Study of binding and neutralising antibodies to interferon-beta in two groups of relapsing-remitting multiple sclerosis patients. J Neural 2001;248:383-8.
50. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904.
51. Cook SD, Quinless JR, Jotkowitz RN, et al. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients. Neurology 2001;57:1080-4.
52. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1 for multiple sclerosis: Results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-60.
53. SPECTRIMS Study Group. Secondary progressive efficacy clinical trial of recombinant interferon-beta-1a in MS (SPECTRIMS) study group. Randomized controlled trial of interferon-beta-la in secondary progressive MS: Clinical results. Neurology 2001;56:1496-1504.
54. Bertolotto A, Malucchi S, Sala A, et al. Differential effects of three interferon betas in neutralising antibodies in patients with multiple sclerosis: A follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 2002;73:148-53.